01
Process chemistry
Route development, non-infringing processes, impurity control, yield improvement and scale-aware chemistry.
R&D & innovation
Research-backed.
Quality-driven.
Built to keep evolving.
Morepen connects process chemistry, analytical science, intellectual property, regulatory documentation and manufacturing readiness to create repeatable value from research.
Science at work
Research that moves
towards execution.
R&D is being positioned as an engine for new products, customer acquisition and higher-value development work—not as an isolated laboratory function.
175Patent filings accumulated across Morepen's research and regulatory journey
408Drug Master Files across international markets
42New molecules launched in the last 5 years
Complex ChemistryHi-Potent Oncology Product pipeline
02
Analytical science
Methods, impurity characterisation, stability, solid-state understanding and development documentation.
03
Quality by development
Quality, compliance and repeatability are designed into development work before transfer into manufacturing.
04
Continuous development
New molecules, international filings, process improvements and formulation-development programs keep the pipeline active.
Patents & intellectual property
IP built around
process understanding.
Morepen's current AGM narrative reports 175 patent filings. The long-running R&D portfolio includes patent families across key APIs, polymorphs and process improvements.
Selected international patent families
Published R&D materials reference filings or grants across markets including the U.S., Canada, Europe, Russia, South Africa, Australia, Japan and India depending on the patent family.
Selected patents granted in India
Research + quality + regulatory
Development discipline
that customers can use.
Research creates value when it can be translated into controlled processes, reproducible analytical methods, regulatory documentation and manufacturing execution.
Regulatory documentation
408 Drug Master Files are referenced across international markets including Europe, Canada, Japan, South Korea and the Middle East.
Quality-controlled development
Process and formulation development are supported by analytical work, stability, impurity understanding and market-specific quality requirements.
Commercial translation
Technology transfer and scale-up connect R&D output with site readiness and commercial execution.
Formulation capability
FY26 formulation-development work strengthened regulated-market filing capability and supported the company's first U.S. ANDA program.
Next line of action
Innovation Hub &
Capability Centre.
Planned as the next step in Morepen's scientific evolution: a closer connection between development, analysis, pilot work, technology transfer and customer collaboration.
Process development
More complex route and process work connected to customer requirements.
Analytical science
Integrated analytical development, impurity understanding and solid-state support.
Pilot-scale work
A stronger bridge between laboratory development and plant-scale execution.
Technology transfer
Structured transfer of chemistry, methods and controls into manufacturing.
Customer collaboration
Move gradually from receiving manufacturing assignments toward developing solutions with customers.
Capability roadmap: Morepen's heritage remains small molecules and process chemistry. Dedicated high-potency and oncology development capability is being strengthened, while peptides, related technologies and selected specialty CDMO capabilities remain areas under evaluation. Future capabilities should be described as planned or exploratory until technically qualified and commercially ready.
Turn science into the next program.
Discuss the chemistry, analytical challenge or development objective you want to move toward scale.